The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . A single-arm, single-blind, phase 2a study of the neuromodulating drug RL-007, initiated by biopharmaceutical ...
REVISED WITH EXTRA COMMENTS 3/16/21 — Results from a phase 2 placebo-controlled trial of the investigational antiamyloid drug donanemab (Eli Lilly and Company) show that the novel agent met the ...
Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito ...
At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than ...
The Alzheimer’s field begins 2021 with a glimmer of good news: Donanemab, a monoclonal antibody that recognizes a pyroglutamated form of Aβ, slowed cognitive decline in people with early AD. That was ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
New Social Security retirement claims rose 13% during a period of agency turmoil, potentially leaving early claimants with permanently smaller checks as Medicare costs increase. Aetna Sets 2032 Goal ...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...
Nuber-Champier, A. et al. (2022) "Monocytosis in the Acute Phase of SARS-CoV-2 Infection Predicts the Presence of Anosognosia for Cognitive Deficits in the Chronic Phase".
A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three ...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...